search icon
  • Print
  • ShareThis
  • Text Size
  • Strengthening U.S. Antibiotic Resistance Efforts

    Antimicrobial resistance is a serious threat to public health, patient safety, and national security.  IDSA is working on multiple fronts to strengthen the United States’ response to antimicrobial resistance including the efforts of the Interagency Task Force on Antimicrobial Resistance [chaired by the Centers for Disease Control and Prevention (CDC), National Institute of Allergy and Infectious Diseases (NIAID), and Food and Drug Administration (FDA)] formed in the late 1990’s as well as the Trans-Atlantic Task Force on Antimicrobial Resistance (TATFAR) formed by the U.S. and European Union in November 2009.  We seek better overall leadership and coordination of U.S. activities, strengthened funding, and enhanced surveillance, prevention and control, data collection, and research efforts. For this reason, IDSA enthusiastically endorses the Strategies to Address Antimicrobial Resistance (STAAR) Act, which, if enacted, would support the Interagency Task Force’s work and elevate the federal response overall. We also seek strengthened federal funding.

    Antimicrobial-resistant infections kill tens of thousands of Americans each year. If you or a loved one has been harmed and you would like to support IDSA’s advocacy efforts by sharing your story, please contact Jennifer Ford at

    IDSA's Efforts in Strengthening the U.S. Response to Antimicrobial Resistance

    IDSA Statement on the Development of the Antibiotic Accelerator

    The Infectious Diseases Society of America (IDSA) commends the Biomedical Advanced Research and Development Authority (BARDA) and the National Institute for Allergy and Infectious Diseases (NIAID) for launching the new Combating Antibiotic Resistant Bacteria (CARB) Biopharmaceutical Accelerator to support antibiotic research and development (R&D).

    IDSA Comments to PACCARB (PDF)

    IDSA presented comments at a public meeting of the Presidential Advisory Council on Antibiotic-Resistant Bacteria (PACCARB).  IDSA applauded the PACCARB for its work so far on the five goals of the National Action Plan for Combating Antibiotic Resistant Bacteria, and highlighted specific recommendations to advance each of the goals in the National Action Plan.

    IDSA Statement presented at the Interagency Task Force on Antimicrobial Resistance (ITFAR) Meeting

    IDSA statement on the current U.S. response to antimicrobial resistance, presented at the ITFAR Meeting, November 15, 2012.

    IDSA Comments on the AR Action Plan (PDF)

    IDSA statement on the Public Health Action Plan to Combat Antimicrobial Resistance at the Interagency Task Force on Antimicrobial Resistance (ITFAR) meeting.

    IDSA Comments to PACCARB on Antibiotic Resistance Data Collection (PDF)

    IDSA comments to the Presidential Advisory Council on Combating Antibiotic-Resistant Bacteria on challenges faced in gathering and sharing antibiotic resistance data.

    IDSA Applauds FDA and NIH for Advancing Federal Dialogue on Antibiotic Resistance (PDF)

    In a letter to U.S. Food and Drug Administration (FDA) commissioner Margaret Hamburg and National Institutes of Health (NIH) director Francis Collins, IDSA thanks the respective agencies for holding a productive and thought provoking public workshop on antimicrobial product development and enthusiastically welcomes NIH’s announcement of a forthcoming public-private partnership (PPP) to address antibiotic development and related effort to establish a master clinical trials protocol. IDSA has long advocated for a high-level PPP with representation from the federal government, academia, industry, physicians and other key stakeholders, to promote innovation and improvement in the discovery, development, and evaluation of new antibiotics and diagnostics.

    IDSA Calls on President Obama to Fulfill SOTU Pledge on Antibiotic Resistance (PDF)

    IDSA applauds President Obama for highlighting the need to address resistance during his State of the Union address and urges him to take specific actions, including incentivizing development of new antibiotics and diagnostics, strengthening stewardship, improving surveillance, and investing in research.

    IDSA Joins Members of Congress in Call for a Hearing on Antimicrobial Resistance (PDF)

    IDSA supports a request from Representatives Waxman, DeGette, Pallone, and Dingell to the House Energy & Commerce Committee that a hearing be held on federal efforts to address antimicrobial resistance.  Both the IDSA letter and the congressional request reference the September 2013 CDC report, Antimicrobial Resistance Threats in the United States, 2013 as evidence of the need for action.

    IDSA Press Release STAAR Act (PDF)

    IDSA applauds Senator Sherrod Brown (D-OH) for reintroducing the Strategies to Address Antimicrobial Resistance (STAAR) Act to provide urgently needed federal leadership to tackle this growing public health crisis.

    STAAR Act Endorsed by 26 Organizations (PDF)

    IDSA and 25 other organizations representing physicians, dentists, hospitals, pharmacists, healthcare epidemiologists, infection prevention and control professionals, and public health experts, patients, and advocates write to thank Senator Sherrod Brown (D-OH) for reintroducing the Strategies to Address Antimicrobial Resistance (STAAR) Act.

    Hunting the Nightmare Bacteria: Who's Tracking the Nightmare Bacteria?

    PBS Frontline highlights the ongoing lack of surveillance data of antimicrobial resistance in the United States.

    IDSA Antimicrobial Resistance Update to Congress (PDF)

    IDSA sent an e-newsletter to Congress urging co-sponsorship of the Strategies to Address Antimicrobial Resistance (STAAR) Act.

    Antibiotic Resistance Threats in the United States, 2013

    CDC report providing a detailed snapshot of the burdens and threats posed by the antibiotic-resistant germs having the most impact on human health. 

    IDSA President Addresses Policymakers (PDF)

    IDSA President David Relman, MD, FIDSA, spoke at a CDC/IDSA/Pew Charitable Trusts congressional briefing on antibiotic resistance and the need for new antibiotics.

    CDC's Vital Signs on Carbapenem-resistant Enterobacteriaceae (CRE)

    CDC reports on untreatable and hard-to-treat infections from CRE bacteria, which are on the rise.  CRE bacteria have become resistant to all or nearly all of the antibiotics we have today.

    Antimicrobial Resistance Fact Sheet (PDF)

    One-page fact sheet on antimicrobial resistance, by IDSA.

| HIVMA | Contact Us

© Copyright IDSA 2017 Infectious Diseases Society of America

Full Site Mobile Site